MedPath

Bio equivalence study of Esomeprazole 40 mg

Not Applicable
Conditions
Bio equivalence Esomeprazole 40 mg.
Registration Number
IRCT20200513047423N3
Lead Sponsor
Sina pishgam daru novin
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
24
Inclusion Criteria

Healthy liver
Healthy Kidney
Observing BMI

Exclusion Criteria

Out of age ranges
smoking
Unhealthy liver and kidney
Pregnancy

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Increasing plasma concentration after administration of esomeprazole capsules till Tmax and then decreasing plasma concentration after Tmax. Timepoint: Initial blood sampling is performed before drug administration to obtain blank plasma chromatogram of each healthy volunteers.Hence the Tmax of esomeprazole is between 1.5 and 2.5 hours, so it is needed to have 5 blood samplings before Tmax. This period of time is called absorption phase.In the elimination phase (after Tmax)blood sampling carry out each hours. Method of measurement: In this study, the variable is plasma concentration of esomeprazole. High performance liquid chromatography is used to determine the concentration of esomeprazole in plasma.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath